JP2023529089A - コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤 - Google Patents

コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤 Download PDF

Info

Publication number
JP2023529089A
JP2023529089A JP2022573437A JP2022573437A JP2023529089A JP 2023529089 A JP2023529089 A JP 2023529089A JP 2022573437 A JP2022573437 A JP 2022573437A JP 2022573437 A JP2022573437 A JP 2022573437A JP 2023529089 A JP2023529089 A JP 2023529089A
Authority
JP
Japan
Prior art keywords
trem
seq
strem
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529089A5 (https=
Inventor
デライブ，マーク
サルセド－マギウッリ，マルガリータ
ガロー，ジーン－ジャック
ラムデン，シモン
オリヴィエ，オーレリー
Original Assignee
イノトレム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノトレム filed Critical イノトレム
Publication of JP2023529089A publication Critical patent/JP2023529089A/ja
Publication of JP2023529089A5 publication Critical patent/JP2023529089A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
JP2022573437A 2020-06-05 2021-06-07 コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤 Pending JP2023529089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305603.1 2020-06-05
EP20305603 2020-06-05
PCT/EP2021/065194 WO2021245291A1 (en) 2020-06-05 2021-06-07 Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023529089A true JP2023529089A (ja) 2023-07-07
JP2023529089A5 JP2023529089A5 (https=) 2024-06-14

Family

ID=71614781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573437A Pending JP2023529089A (ja) 2020-06-05 2021-06-07 コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤

Country Status (6)

Country Link
US (1) US20230201301A1 (https=)
EP (1) EP4161551A1 (https=)
JP (1) JP2023529089A (https=)
CN (1) CN116490199A (https=)
CA (1) CA3180293A1 (https=)
WO (1) WO2021245291A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533791A (ja) * 2012-09-07 2015-11-26 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） 骨髄細胞に発現する誘発性受容体１（ｔｒｅｍ−１）ｔｒｅｍ様転写産物１（ｔｌｔ−１）に由来する阻害ペプチドおよびその使用
JP2016169208A (ja) * 2010-04-08 2016-09-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
WO2020065044A1 (en) * 2018-09-28 2020-04-02 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
US10765679B2 (en) * 2015-07-04 2020-09-08 Emory University Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016169208A (ja) * 2010-04-08 2016-09-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔｒｅｍ様転写物１（ｔｌｔ−１）から誘導された阻害性ペプチドおよびその使用
JP2015533791A (ja) * 2012-09-07 2015-11-26 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） 骨髄細胞に発現する誘発性受容体１（ｔｒｅｍ−１）ｔｒｅｍ様転写産物１（ｔｌｔ−１）に由来する阻害ペプチドおよびその使用
WO2020065044A1 (en) * 2018-09-28 2020-04-02 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMJ OPEN, vol. 6, JPN6025027508, 2016, pages 010314 - 1, ISSN: 0005787210 *
FRONTIERS IN CARDIOVASCULAR MEDICINE, vol. 7, JPN6025027507, April 2020 (2020-04-01), pages 78 - 1, ISSN: 0005787209 *
THE LANCET, vol. 395, JPN6025027509, March 2020 (2020-03-01), pages 1054 - 1062, ISSN: 0005787211 *

Also Published As

Publication number Publication date
CN116490199A (zh) 2023-07-25
CA3180293A1 (en) 2021-12-09
EP4161551A1 (en) 2023-04-12
US20230201301A1 (en) 2023-06-29
WO2021245291A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
Sokolowska et al. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI)
Lim et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency
EP2115478B1 (en) Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular diseases
Dai et al. Apolipoprotein AI attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony–stimulating factor–dependent mechanism
US12364733B1 (en) Method for treating septic shock
JP6458087B2 (ja) 院内感染に対する易感染性を判定するための方法
AU2021251382B2 (en) Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS)
Takahashi et al. Osteopontin is involved in migration of eosinophils in asthma
TW202402790A (zh) 減少呼吸系統感染之方法
Zhu et al. HMGB1 regulates Th17 cell differentiation and function in patients with psoriasis
Huang et al. A pilot study on primary cultures of human respiratory tract epithelial cells to predict patients’ responses to H7N9 infection
AL-SALIH et al. Identify Human Cluster of differentiation 147 (CD147), a New Target of SARS-CoV-2 Invasion.
JP2023529089A (ja) コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤
Mitsui et al. CiDRE+ M2c macrophages hijacked by SARS-CoV-2 cause COVID-19 severity
JP2024177937A (ja) 肺炎を予測するためのバイオマーカー
JP2023528069A (ja) コロナウイルス感染症罹患対象の重症度又は合併症のマーカーとしての可溶性ｔｒｅｍ－１
WO2021247454A1 (en) Methods and treatment involving antibodies to il-18
VOICULESCU et al. Significance of Hematological Parameters and Biochemical Markers in Severe Forms of Covid-19
AU2013200398B2 (en) Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Marker for Diseases
Bean Investigating the components of heterotypic immunity associated with protection against coronavirus related disease
Khafeef Study The Role of Some Factors in Genetic Variations and The Rate of COVID-19 Virus
Gao Immunological Regulation Mechanisms of Interleuking-38 and Meteorin-β (Metrnβ)/IL-41 in the Pathophysiology of Respiratory Diseases
Ting et al. The Bidirectional Association Between Periodontitis and COVID-19: A Review of Current Evidence
CN116507915A (zh) 可溶性trem-1作为患有冠状病毒感染的受试者的严重程度或并发症的标志物
Pitzer Contribution of ASC-Inflammasome to Vascular Endothelial Dysfunction: Role of RNA Receptor RIG-I

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260203